UPCOMING SESSIONS in ET
Tue, Sep 1, 2026
5:00 – 6:00 AM Bangkok
Understanding Your Care Journey: From Testing to Treatment Brian L. Miller II Click Here To Register
UPCOMING SESSIONS in ET
Tue, Sep 1, 2026 · 5:00 – 6:00 AM Bangkok
Understanding Your Care Journey: From Testing to Treatment
Brian L. Miller II
Click Here To Register
View all sessions

Impact of hydroxyurea use on severity and hematologic profile in children with sickle cell disease at University of Benin Teaching Hospital, Benin city, Nigeria

Source
International Journal Of Contemporary Pediatrics

Abstract

Background: Sickle cell disease (SCD) is a major cause of morbidity and mortality among children in sub-Saharan African. Hydroxyurea (HU) remains the cornerstone of disease- modifying therapy, but its utilization, hematologic impact and relationship with disease severity among Nigerian children are not fully characterized. This study assessed the impact of hydroxyurea use on disease severity and haematologic profile in children with SCD attending the University of Benin of teaching Hospital, Benin city.

Methods: This cross- sectional study included 225 children with SCA aged 1-18 years in steady state. Data were obtained on socio- demographic characteristics, HU use and disease severity were using structured proforma and medical records. Disease severity was assessed using Adegoke’s scoring system while haematologic parameters including Packed cell volume and White blood cell counts were documented. Statistical associations between HU, hematologic indices and disease severity were analysed using Chi-square tests, with significance set at p<0.05.